Advancing science. Improving connections.
We focus our research and development efforts on rare (affecting fewer than 200K patients in the U.S.) and near-rare (affecting around one million patients) neuropsychiatric conditions.
Our lead product candidate, ZygelTM is a cannabidiol gel currently being evaluated for Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), and 22q.
Clinical Pipeline and Expected Milestones